

Andre H Goy

List of Publications by Citations

Source: <https://exaly.com/author-pdf/60064/andre-h-goy-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

305
papers

18,300
citations

54
h-index

133
g-index

326
ext. papers

22,130
ext. citations

4.5
avg, IF

6.04
L-index

#	Paper	IF	Citations
305	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 2531-2544	59.2	2326
304	Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. <i>Journal of Clinical Oncology</i> , 2015 , 33, 540-9	2.2	1155
303	Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. <i>New England Journal of Medicine</i> , 2013 , 369, 507-16	59.2	1139
302	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 31-42	21.7	796
301	PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma. <i>New England Journal of Medicine</i> , 2014 , 370, 1008-18	59.2	784
300	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015 , 21, 922-6	50.5	707
299	Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4867-74	2.2	600
298	Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 667-75	2.2	465
297	High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7013-23	2.2	458
296	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2020 , 382, 1331-1342	59.2	448
295	Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1182-9	2.2	442
294	Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1112-21	2.2	391
293	A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. <i>Blood</i> , 2001 , 97, 616-23	2.2	329
292	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncology, The</i> , 2016 , 17, 200-211	21.7	314
291	Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3688-95	2.2	269
290	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015 , 126, 739-45	2.2	268
289	Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3776-85	2.2	263

288	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2018 , 391, 659-667	4.0	231
287	Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. <i>Cancer</i> , 2011 , 117, 5058-66	6.4	226
286	Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. <i>Blood</i> , 2004 , 104, 3483-9	2.2	222
285	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018 , 103, 874-879	6.6	219
284	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. <i>Science Immunology</i> , 2020 , 5,	2.8	217
283	Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. <i>Cancer</i> , 2003 , 97, 586-91	6.4	202
282	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3119-3128	2.2	197
281	Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine. <i>Journal of Clinical Bioinformatics</i> , 2015 , 5, 4		175
280	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e603-e612	14.2	173
279	Postibrutinib outcomes in patients with mantle cell lymphoma. <i>Blood</i> , 2016 , 127, 1559-63	2.2	171
278	Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 150, 200-8	4.5	168
277	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. <i>Blood</i> , 2011 , 118, 5119-25	2.2	152
276	A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. <i>Cancer</i> , 2003 , 98, 310-4	6.4	141
275	Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1682-8	2.2	140
274	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. <i>Blood</i> , 2016 , 128, 2199-2205	2.2	135
273	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3467-74	2.2	129
272	Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. <i>Cancer</i> , 2003 , 98, 1196-205	6.4	128
271	Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2007 , 136, 439-47	4.5	124

270	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. <i>Blood</i> , 2010 , 116, 1025-34	2.2	120
269	A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. <i>Clinical Cancer Research</i> , 2012 , 18, 4830-40	12.9	117
268	Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2015 , 170, 504-14	4.5	112
267	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2020 , 7, e511-e522	14.6	97
266	Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. <i>Oncotarget</i> , 2016 , 7, 44735-44762	3.3	94
265	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018 , 103, 1511-1517	6.6	91
264	Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4095-102	2.2	91
263	Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5023-30	2.2	83
262	Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. <i>British Journal of Haematology</i> , 2017 , 179, 430-438	4.5	77
261	Ovarian cancer biomarkers for molecular biosensors and translational medicine. <i>Expert Review of Molecular Diagnostics</i> , 2010 , 10, 1069-83	3.8	76
260	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019 , 133, 1964-1976	2.2	72
259	Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016 , 172, 80-8	4.5	67
258	Early detection biomarkers for ovarian cancer. <i>Journal of Oncology</i> , 2012 , 2012, 709049	4.5	64
257	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. <i>Blood</i> , 2018 , 132, 91-91	2.2	64
256	Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. <i>Cancer</i> , 2008 , 112, 831-6	6.4	62
255	Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2014 , 32, 489-99	4.3	61
254	Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. <i>Blood</i> , 2012 , 119, 4123-8	2.2	60
253	A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1373-9	1.9	55

252	Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. <i>Haematologica</i> , 2019 , 104, e211-e214	6.6	55
251	Protein calorie malnutrition, nutritional intervention and personalized cancer care. <i>Oncotarget</i> , 2017 , 8, 24009-24030	3.3	53
250	CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 866-77	2.9	53
249	Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. <i>Blood</i> , 2019 , 134, 1024-1036	2.2	51
248	Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017 , 23, 1167-1176	12.9	50
247	Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. <i>Oncotarget</i> , 2015 , 6, 28693-715	3.3	45
246	Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 151, 47-53	4.5	44
245	Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?. <i>British Journal of Haematology</i> , 2006 , 134, 391-8	4.5	44
244	Mantle cell lymphoma: the promise of new treatment options. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 69-86	7	43
243	A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 392-7	2	41
242	BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study. <i>Blood</i> , 2015 , 126, 1491-1491 ²	4.2	40
241	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , 2019 , 33, 2762-2766	10.7	39
240	Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. <i>Journal of Infectious Diseases</i> , 2006 , 194, 1394-7	7	39
239	The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1211-6	4.7	38
238	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019 , 25, 4264-4270	12.9	37
237	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018 , 93, 1394-1401	7.1	37
236	Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. <i>Cancer</i> , 2012 , 118, 3565-70	6.4	37
235	Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2014 , 166, 77-83	4.5	35

234	A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2761-8	1.9	35
233	Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. <i>Oncotarget</i> , 2016 , 7, 48692-48731	3.3	34
232	Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. <i>Oncologist</i> , 2012 , 17, 694-707	5.7	33
231	A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. <i>British Journal of Haematology</i> , 2016 , 174, 571-81	4.5	33
230	Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 696-705 ^{3.8}		31
229	Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. <i>British Journal of Haematology</i> , 2015 , 170, 496-503	4.5	30
228	Cancer Tissue Engineering: A Novel 3D Polystyrene Scaffold for In Vitro Isolation and Amplification of Lymphoma Cancer Cells from Heterogeneous Cell Mixtures. <i>Journal of Tissue Engineering</i> , 2011 , 2011, 362326	7.5	30
227	Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020 , 95, 18-27	7.1	30
226	Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine. <i>Journal of Oncology</i> , 2013 , 2013, 368751	4.5	28
225	Bortezomib in mantle cell lymphoma. <i>Future Oncology</i> , 2008 , 4, 149-68	3.6	28
224	Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2007 , 138, 502-5	4.5	28
223	Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. <i>European Journal of Cancer</i> , 2006 , 42, 2976-81	7.5	28
222	Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. <i>British Journal of Haematology</i> , 2014 , 165, 510-8	4.5	27
221	Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. <i>Journal of Ovarian Research</i> , 2014 , 7, 109	5.5	27
220	Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2013 , 121, 2864-74	2.2	27
219	Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1269-77	1.9	27
218	A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2863-9	1.9	26
217	Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). <i>Journal of Hematology and Oncology</i> , 2017 , 10, 171	22.4	25

216	Phase 1 Single Agent Antitumor Activity of Twice Weekly Consecutive Day Dosing of the Proteasome Inhibitor Carfilzomib (PR-171) in Hematologic Malignancies.. <i>Blood</i> , 2007 , 110, 411-411	2.2	25
215	A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012 , 53, 254-8	1.9	24
214	Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Blood</i> , 2019 , 134, 245-245	2.2	24
213	First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3K In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies. <i>Blood</i> , 2013 , 122, 678-678	2.2	24
212	Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. <i>Blood</i> , 2016 , 128, LBA-6-LBA-6	2.2	24
211	Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014 , 124, 550-550	2.2	23
210	Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine. <i>Oncotarget</i> , 2016 , 7, 67551-67573	3.3	23
209	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. <i>Clinical Immunology</i> , 2014 , 154, 37-46	9	22
208	Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2013 , 152, 631-8	4.5	22
207	Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2015 , 90, 487-92	7.1	22
206	The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma. <i>Cancer</i> , 2006 , 108, 10-20	6.4	22
205	The serine protease prostaticin (PRSS8) is a potential biomarker for early detection of ovarian cancer. <i>Journal of Ovarian Research</i> , 2016 , 9, 20	5.5	22
204	Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 62	22.4	21
203	Mantle cell lymphoma: biological insights and treatment advances. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 267-77		20
202	Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2019 , 134, 763-763	2.2	20
201	Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients [An Observational Study		20
200	Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. <i>American Journal of Pathology</i> , 2004 , 164, 2251-8	5.8	19
199	Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. <i>Investigational New Drugs</i> , 2014 , 32, 1213-25	4.3	18

198	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019 , 3, 1568-1573	7.8	18
197	Mantle cell lymphoma: state of the art. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 44-55	0.6	18
196	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma. <i>JCI Insight</i> , 2021 , 6,	9.9	17
195	Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. <i>Clinical Cancer Research</i> , 2015 , 21, 3853-61	12.9	16
194	Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. <i>Blood</i> , 2021 , 137, 1832-1835	2.2	16
193	New directions in the treatment of mantle cell lymphoma: an overview. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 7 Suppl 1, S24-32		16
192	KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. <i>Blood</i> , 2019 , 134, 754-754	2.2	16
191	Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study. <i>Blood</i> , 2011 , 118, 269-269	2.2	16
190	Mantle cell lymphoma: evolving novel options. <i>Current Oncology Reports</i> , 2007 , 9, 391-8	6.3	14
189	Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 5104-5104	2.2	14
188	The role of the ubiquitin proteasome system in lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 87, 306-22	7	13
187	Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2018 , 132, 2876-2876	2.2	13
186	Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia 2021 , 9,		13
185	High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. <i>British Journal of Haematology</i> , 2017 , 177, 263-270	4.5	12
184	Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. <i>American Journal of Hematology</i> , 2017 , 92, E575-E583	7.1	12
183	Expanding therapeutic options in mantle cell lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7 Suppl 5, S184-91		12
182	Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up. <i>Blood</i> , 2019 , 134, 1538-1538	2.2	12
181	The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. <i>Blood</i> , 2011 , 118, 442-442	2.2	12

180	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 194, 690-700	4.5	12
179	Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. <i>Cancer</i> , 2018 , 124, 2561-2569	6.4	11
178	2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2018 , 132, 2967-2967	2.2	11
177	Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. <i>Blood</i> , 2012 , 120, 904-904	2.2	11
176	Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. <i>Blood</i> , 2014 , 124, 4453-4453	2.2	11
175	Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. <i>Blood</i> , 2014 , 124, 4471-4471	2.2	11
174	Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K- γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. <i>Blood</i> , 2016 , 128, 2979-2979 ²	2.2	11
173	FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 372-381	1.9	10
172	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	10
171	Informatics-guided procurement of patient samples for biomarker discovery projects in cancer research. <i>Cell and Tissue Banking</i> , 2009 , 10, 43-8	2.2	10
170	Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.. <i>Blood</i> , 2007 , 110, 3449-3449	2.2	10
169	Long-Term (4 Year and 8 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021 , 138, 1764-1764	2.2	10
168	Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancer. <i>Breast</i> , 2018 , 39, 101-109	3.6	9
167	Sequential single-agent obatoclox mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2932-4	1.9	9
166	Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 481-5	1.9	9
165	Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.. <i>Blood</i> , 2006 , 108, 2742-2742	2.2	9
164	A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. <i>Blood</i> , 2009 , 114, 3693-3693	2.2	9
163	Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2014 , 124, 1708-1708	2.2	9

162	Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. <i>Blood</i> , 2015 , 126, 719-719	2.2	9
161	Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 3032-3032	2.2	9
160	Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3188-3197	1.9	9
159	Osteomyelitis of the patella caused by <i>Legionella anisa</i> . <i>Journal of Clinical Microbiology</i> , 2013 , 51, 2791-397	3.7	8
158	Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2606-12	1.9	8
157	Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen. <i>Blood</i> , 2020 , 136, 39-41	2.2	8
156	Sensitivity, Schedule-Dependence and Molecular Effects of the Proteasome Inhibitor Bortezomib in Non-Hodgkin Lymphoma Cells.. <i>Blood</i> , 2004 , 104, 1387-1387	2.2	8
155	A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma.. <i>Blood</i> , 2007 , 110, 2569-2569	2.2	8
154	Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial. <i>Blood</i> , 2010 , 116, 430-430	2.2	8
153	Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2075-2081	1.9	7
152	A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes. <i>Melanoma Research</i> , 2015 , 25, 376-89	3.3	7
151	Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies [CPIT-001 Trial. <i>Blood</i> , 2018 , 132, 256-256	2.2	7
150	Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results.. <i>Blood</i> , 2006 , 108, 694-694	2.2	7
149	Dose Intensive Induction Followed By Allogeneic Stem Cell Transplantation More Than Doubles Progression-Free and Overall Survival In Double-Hit Lymphoma (DHL). <i>Blood</i> , 2013 , 122, 2141-2141	2.2	7
148	Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2013 , 122, 85-85	2.2	7
147	Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015 , 126, 1528-1528	2.2	7
146	Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study. <i>Blood</i> , 2016 , 128, 623-623	2.2	7
145	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study		7

144	Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2019 , 134, 761-761	2.2	6
143	A Phase I Study of Bortezomib (Velcade®) Plus 90yttrium Labeled Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2008 , 112, 4944-4944	2.2	6
142	Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF). <i>Blood</i> , 2010 , 116, 1762-1762	2.2	6
141	A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2012 , 120, 59-59	2.2	6
140	A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2016 , 128, 473-473	2.2	6
139	ABVD plus rituximab ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. <i>Haematologica</i> , 2019 , 104, e65-e67	6.6	6
138	Mantle Cell Lymphoma: Is It Time for a New Treatment Paradigm?. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 1345-1370	3.1	5
137	Establishment and characterization of a new mantle cell lymphoma cell line M-1. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1255-60	1.9	5
136	Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018 , 132, 4144-4144	2.2	5
135	Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2008 , 112, 3051-3051	2.2	5
134	A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.. <i>Blood</i> , 2009 , 114, 3742-3742	2.2	5
133	A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2012 , 120, 1623-1623	2.2	5
132	Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study. <i>Blood</i> , 2016 , 128, 1786-1786	2.2	5
131	Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7566-7566	2.2	5
130	Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 391-403		5
129	A Patient-Reported Outcome Instrument to Assess Symptom Burden and Predict Survival in Patients with Advanced Cancer: Flipping the Paradigm to Improve Timing of Palliative and End-of-Life Discussions and Reduce Unwanted Health Care Costs. <i>Oncologist</i> , 2019 , 24, 76-85	5.7	5
128	Lenalidomide for mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2015 , 8, 257-64	2.8	4
127	KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, S1	4.7	4

126	Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2185-9	1.9	4
125	A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis.. <i>Blood</i> , 2006 , 108, 2461-2461	2.2	4
124	Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study.. <i>Blood</i> , 2007 , 110, 125-125	2.2	4
123	Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease. <i>Blood</i> , 2015 , 126, 99-99	2.2	4
122	Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7525-7525	2.2	4
121	Targeting indolent non-Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2017 , 10, 299-313	2.8	3
120	Treatment of Peripheral T-Cell Lymphoma in Community Settings. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 354-361	2	3
119	Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S316	2	3
118	Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). <i>Blood</i> , 2020 , 136, 40-42	2.2	3
117	COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study. <i>Blood</i> , 2020 , 136, 6-7	2.2	3
116	High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A).. <i>Blood</i> , 2005 , 106, 2446-2446	2.2	3
115	Phase II Study of Sphingosomal Vincristine in CHOP+/ [Rituximab for Patients with Aggressive Non-Hodgkin Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients.. <i>Blood</i> , 2005 , 106, 943-943	2.2	3
114	Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies.. <i>Blood</i> , 2006 , 108, 2430-2430	2.2	3
113	Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19554-e19554	2.2	3
112	Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e19052-e19052	2.2	3
111	ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS3102-TPS3102	2.2	3
110	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 111	22.4	3
109	Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. <i>Pharmaceutical Research</i> , 2019 , 36, 93	4.5	2

108	Contemporary management of nodal and primary splenic marginal zone lymphoma. <i>Expert Review of Hematology</i> , 2019 , 12, 1011-1022	2.8	2
107	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study. <i>Blood</i> , 2020 , 136, 38-39	2.2	2
106	Abstract 3776: Antitumor response to inotuzumab ozogamicin (INO) in patients with refractory or relapsed indolent B-cell non-Hodgkin's lymphomas (NHL): Pharmacokinetic-pharmacodynamic (PK-PD) modeling and interim results from a phase II study 2012 ,		2
105	The iR2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 402-402	2.2	2
104	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018 , 132, 3142-3142	2.2	2
103	Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. <i>Blood</i> , 2018 , 132, 1677-1677	2.2	2
102	Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).. <i>Blood</i> , 2006 , 108, 2749-2749	2.2	2
101	Short-Term Exposure to Arginine Butyrate, in Combination with Ganciclovir, Is as Effective as Continuous Exposure for Virus-Targeted Therapy of EBV-Positive Lymphomas.. <i>Blood</i> , 2009 , 114, 4754-4754	2.2	2
100	Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens. <i>Blood</i> , 2010 , 116, 1753-1753	2.2	2
99	Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.. <i>Blood</i> , 2010 , 116, 2799-2799	2.2	2
98	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy. <i>Blood</i> , 2010 , 116, 2883-2883	2.2	2
97	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy. <i>Blood</i> , 2011 , 118, 2718-2718	2.2	2
96	Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib. <i>Blood</i> , 2013 , 122, 3057-3057	2.2	2
95	Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma. <i>Blood</i> , 2014 , 124, 3033-3033	2.2	2
94	Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2015 , 126, 2743-2743	2.2	2
93	Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. <i>Blood</i> , 2015 , 126, 2936-2936	2.2	2
92	A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8518-8518	2.2	2
91	Prognostic value of the absolute lymphocyte to monocyte (ALC/AMC) ratio on overall survival among patients with mantle cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e19030-e19030	2.2	2

90	A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR2 Regimen. <i>Blood</i> , 2014 , 124, 4678-4678	2.2	2
89	Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1968-1972	1.9	1
88	To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2019 , 25, 1027-1030 ¹	1.7	1
87	Prediction of clinical outcomes using the pyrolysis, gas chromatography, and differential mobility spectrometry (Py-GC-DMS) system. <i>Journal of Analytical and Applied Pyrolysis</i> , 2016 , 119, 189-198	6	1
86	Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszczą Wyniki międzynarodowego, wieloośrodkowego, badania II fazy z ibrutynibem (PCI-32765) EHA Encore. <i>Acta Haematologica Polonica</i> , 2013 , 44, 314-318	0.4	1
85	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.. <i>Blood Cancer Journal</i> , 2022 , 12, 25	7	1
84	Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study. <i>Blood</i> , 2019 , 134, 5333-5333	2.2	1
83	Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL).. <i>Blood</i> , 2009 , 114, 1678-1678	2.2	1
82	Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy. <i>Blood</i> , 2010 , 116, 521-521	2.2	1
81	High-Resolution Sequencing Identifies NOXA1 De-Methylation As a Novel Strategy to Overcome Bortezomib Resistance in Mantle Cell Lymphoma. <i>Blood</i> , 2011 , 118, 557-557	2.2	1
80	Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies. <i>Blood</i> , 2012 , 120, 1936-1936	2.2	1
79	Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant. <i>Blood</i> , 2012 , 120, 3710-3710	2.2	1
78	Relapses of Diffuse Large B Cell Lymphoma in Rituximab Era Are Limited to the First Two Years after Frontline Therapy. <i>Blood</i> , 2014 , 124, 1307-1307	2.2	1
77	Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices. <i>Blood</i> , 2014 , 124, 1740-1740	2.2	1
76	Front-Line, Dose-Escalated Immunochemotherapy Is Associated with a Significant PFS (but not OS) Advantage in 401 Patients (Pts) with Double-Hit Lymphomas (DHL): A Systematic Review and Meta-Analysis. <i>Blood</i> , 2014 , 124, 3056-3056	2.2	1
75	Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2016 , 128, 2973-2973	2.2	1
74	Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8534-8534	2.2	1
73	Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8500-8500	2.2	1

72	Are patients with advanced cancer concerned about financial toxicity?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10065-10065	2.2	1
71	Comparable outcomes in CLL patients treated with reduced-dose ibrutinib: Results from a multi-center study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7529-7529	2.2	1
70	Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6). <i>Blood</i> , 2021 , 138, 2832-2832	2.2	1
69	Adhering to Recommended Lifestyle Changes and Medications 9 Months to 3 Years after Hematopoietic Stem Cell Transplant: Self-Reported Adherence and the Practical, Psychological, and Social Correlates of Adherence. <i>Blood</i> , 2018 , 132, 4799-4799	2.2	1
68	Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome. <i>Blood</i> , 2012 , 120, 1579-1579	2.2	1
67	The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020 , 10, 1-5	2.6	1
66	Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2021 , 14, 927-943	2.8	1
65	Update in the management of mantle cell lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 297-9	0.6	1
64	Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up.. <i>HemaSphere</i> , 2022 , 6, e712	0.3	1
63	Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma. <i>PET Clinics</i> , 2012 , 7, 57-65	2.2	0
62	Autologous stem cell transplantation in multiple myeloma patients over age 75.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8025-8025	2.2	0
61	Evomela [®] Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2019 , 134, 3316-3316	2.2	0
60	Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2014 , 124, 4461-4461	2.2	0
59	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2625-2636	1.9	0
58	Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2255-2263	1.9	
57	Liquid tumors in the elderly. <i>Clinics in Geriatric Medicine</i> , 2012 , 28, 115-52	3.8	
56	Mantle cell lymphoma: continuously improving the odds!. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 1001-1018		
55	Are we improving the survival of patients with mantle cell lymphoma: if so, what is the explanation?. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1828-30	1.9	

54	Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. <i>Blood</i> , 2020 , 136, 34-35	2.2
53	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. <i>Blood</i> , 2020 , 136, 5-6	2.2
52	Higher Incidence of Germline Mutations in DNA Damage Response Genes in Lymphoid Than in Myeloid Neoplasms without Significant Increase in the Prevalence of Clonal Hematopoiesis. <i>Blood</i> , 2020 , 136, 4-5	2.2
51	5-Azacitidine Therapy in Elderly Patients with Acute Myelogenous Leukemia Yields Similar Survival Compared to 3+7 Induction Chemotherapy with Less Transfusional Support, Bacteremias, and Hospital Days.. <i>Blood</i> , 2006 , 108, 4569-4569	2.2
50	Phase II Study of Denileukin Diftitox (ONTAK [®]) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin [®] Lymphoma (B-NHL) and Poor Bone Marrow Reserve.. <i>Blood</i> , 2006 , 108, 4724-4724	2.2
49	Cryopreservation of Peripheral Blood Stem Cells (PBSC) with Hydroxyethylstarch (HES) and Dimethylsulfoxide (DMSO) Results in Faster Granulocyte Recovery Than Using Dimethylsulfoxide Alone.. <i>Blood</i> , 2007 , 110, 3287-3287	2.2
48	DCEP (Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin) Followed by High-Dose G-CSF Is a Highly Efficient and Safe Regimen for Stem Cell Mobilization for Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 3284-3284	2.2
47	The effect of duvelisib, a dual inhibitor of PI3K- γ on components of the tumor microenvironment in previously untreated follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7579-7579	2.2
46	Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma and Lymphoma. <i>Blood</i> , 2018 , 132, 2131-2131	2.2
45	Evaluation of T Cell and Monocyte Immune Subsets in the Stem Cell Product of Patients Developing Engraftment Syndrome Following Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma. <i>Blood</i> , 2018 , 132, 4604-4604	2.2
44	Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8554-8554	2.2
43	Post-treatment PET scan is highly predictive of outcome (PFS and OS) in MCL pts treated with R-Hyper-CVAD in the frontline setting regardless of MIPI score.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8557-8557	2.2
42	Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19561-e19561	2.2
41	A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin [®] Lymphoma. <i>Blood</i> , 2014 , 124, 3089-3089	2.2
40	Bendamustine Plus Rituximab (BR) in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma of a Phase 2 Study: Multivariate Analysis and Updated Final Results By Subgroup. <i>Blood</i> , 2014 , 124, 1757 ² -1757	2.2
39	Prevalence of clinically meaningful prognostic variability in cancer: An analysis using a new taxonomy system.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17699-e17699	2.2
38	Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2015 , 126, 2938-2938	2.2
37	Patterns of Treatment for Newly Diagnosed and Relapsed/Refractory Peripheral T-Cell Lymphoma in the Community Setting. <i>Blood</i> , 2015 , 126, 3952-3952	2.2

36	Clinical Impact of Internet-Based Tools to Help Guide Therapeutic Decisions for Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2015 , 126, 4527-4527	2.2
35	Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial. <i>Blood</i> , 2015 , 126, 1732-1732	2.2
34	Outcomes of Salvage Stem Cell Transplantation in Hodgkin Lymphoma in a Single Institution in the Modern Era. <i>Blood</i> , 2015 , 126, 5500-5500	2.2
33	Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7545-7545	2.2
32	High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation and Receive Salvage with Donor T Lymphocyte Infusions (DLI). <i>Blood</i> , 2016 , 128, 5860-5860	2.2
31	Long-Term Survival and Absence of Late Relapses in Patients Who Underwent Allogeneic Stem Cell Transplantation for Advanced Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 5843-5843	2.2
30	5-Day Decitabine with Mini Fludarabine and Busulfan Yields Comparable Outcomes to Mini Flu/Bu but with Increased Incidence of Severe Acute GvHD. <i>Blood</i> , 2016 , 128, 3422-3422	2.2
29	Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. <i>Blood</i> , 2016 , 128, 4403-4403	2.2
28	Long-Term Survival Is Demonstrated in Patients with Multiple Myeloma Treated with Allogeneic Hematopoietic Stem Cell Transplantation in Both the Consolidation and Salvage Settings. <i>Blood</i> , 2016 , 128, 2302-2302	2.2
27	Interim or End of Treatment FGD-PET Complete Response Does Not Have Adequate Predictive Value in Mature T/NK Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1813-1813	2.2
26	Venous Assessment Prior to Mobilization Significantly Reduced Use of Apheresis Central Venous Catheters. <i>Blood</i> , 2016 , 128, 5735-5735	2.2
25	Predictive value of the patient reported outcome 'Living with cancer' instrument on overall survival in advanced cancer patients: A tool for guiding timing of palliative care consultations.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10025-10025	2.2
24	Outcome of Patients with Myeloproliferative Disorders Treated with Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008 , 112, 2797-2797	2.2
23	Combination Melphalan and Bortezomib Conditioning with Autologous Hematopoietic Stem Cell Support in Patients with Advanced Multiple Myeloma. A Phase I/II Study.. <i>Blood</i> , 2009 , 114, 1214-1214	2.2
22	Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.. <i>Blood</i> , 2009 , 114, 673-673	2.2
21	Bortezomib in Mantle Cell Lymphoma 2011 , 107-121	
20	Post-Treatment (not interim) PET-CT Scan Status Is Highly Predictive of Outcome In Mantle Cell Lymphoma Treated with R-Hypercvad or ASCT. <i>Blood</i> , 2010 , 116, 3131-3131	2.2
19	A Novel 3D Co-Culture System for Isolation and Amplification of Primary Liquid Cancer Cells. <i>Blood</i> , 2010 , 116, 426-426	2.2

18	Infections in Patients with Hematologic Malignancies Treated with Monoclonal Antineoplastic Therapy 2011 , 47-66	
17	A Decade of Stem Cell Transplantation in Lymphoma: Single Center Experience and Outcome of 938 Consecutive Allogeneic and Autologous Hematopoietic Stem Cell Transplants Performed At John Theurer Cancer Center. <i>Blood</i> , 2011 , 118, 3086-3086	2.2
16	Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL). <i>Blood</i> , 2011 , 118, 882-882	2.2
15	High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma. <i>Blood</i> , 2011 , 118, 585-585	2.2
14	Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.. <i>Blood</i> , 2012 , 120, 2751-2751	2.2
13	Phase 1b Study of TRU-016, an Anti-CD37 SMIP Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma. <i>Blood</i> , 2012 , 120, 3678-3678	2.2
12	Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients. <i>Blood</i> , 2012 , 120, 3658-3658	2.2
11	SOX11 Directly Represses Wnt/ECatenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment. <i>Blood</i> , 2012 , 120, 895-895	2.2
10	Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population. <i>Blood</i> , 2012 , 120, 4269-4269	2.2
9	Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.. <i>Blood</i> , 2012 , 120, 2728-2728	2.2
8	Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT. <i>Blood</i> , 2012 , 120, 471-471	2.2
7	Overview Of The Genomic Landscape Of High Risk Diffuse Large B-Cell Lymphoma Using Targeted DNA and RNA Sequencing. <i>Blood</i> , 2013 , 122, 501-501	2.2
6	Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin Lymphomas. <i>Blood</i> , 2013 , 122, 3033-3033	2.2
5	Reply to H. Tilly et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 923-925	2.2
4	Mantle cell lymphoma: the changing landscape. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11 Suppl 14, 11-5	0.6
3	Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic.. <i>Journal of Oncology</i> , 2022 , 2022, 8798306	4.5
2	Mantle cell lymphoma308-337	
1	Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. <i>HemaSphere</i> , 2022 , 6, e719	0.3

